Literature DB >> 8040662

Gemcitabine: current status of phase I and II trials.

S B Kaye.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8040662     DOI： 10.1200/JCO.1994.12.8.1527

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  18 in total

1.  Gemcitabine as prolonged infusion and vinorelbine in anthracycline and/or taxane pretreated metastatic breast cancer: a phase II study.

Authors:  Peter Schmid; Volker Heilmann; Carsten-Oliver Schulz; Annette Dieing; Silvia Lehenbauer-Dehm; Christian Jehn; Orhan Sezer; Kurt Possinger; Bernd Flath
Journal:  J Cancer Res Clin Oncol       Date:  2005-10-20       Impact factor: 4.553

2.  Gemcitabine and mitoxantrone in metastatic breast cancer: a phase-I-study.

Authors:  Peter Schmid; Bernd Flath; Konstantin Akrivakis; Volker Heilmann; Hans-Günther Mergenthaler; Orhan Sezer; Rolf Kreienberg; Kurt Possinger
Journal:  Invest New Drugs       Date:  2005-08       Impact factor: 3.850

Review 3.  Promising new agents in the treatment of non-small cell lung cancer.

Authors:  M J Edelman; D R Gandara
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

4.  NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers.

Authors:  Yaacov Richard Lawrence; Bhadrasain Vikram; James J Dignam; Arnab Chakravarti; Mitchell Machtay; Boris Freidlin; Naoko Takebe; Walter J Curran; Soren M Bentzen; Paul Okunieff; C Norman Coleman; Adam P Dicker
Journal:  J Natl Cancer Inst       Date:  2012-12-10       Impact factor: 13.506

Review 5.  Emerging drug treatments for solid tumours.

Authors:  J H Schellens; L C Pronk; J Verweij
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

6.  Stearoyl gemcitabine nanoparticles overcome resistance related to the over-expression of ribonucleotide reductase subunit M1.

Authors:  Woon-Gye Chung; Michael A Sandoval; Brian R Sloat; Dharmika S P Lansakara-P; Zhengrong Cui
Journal:  J Control Release       Date:  2011-08-07       Impact factor: 9.776

Review 7.  Clinical pharmacokinetics of nucleoside analogues: focus on haematological malignancies.

Authors:  S A Johnson
Journal:  Clin Pharmacokinet       Date:  2000-07       Impact factor: 6.447

Review 8.  Gemcitabine and radiosensitization in human tumor cells.

Authors:  D S Shewach; T S Lawrence
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

9.  Prolonged infusion of gemcitabine in advanced solid tumors: a phase-I-study.

Authors:  Peter Schmid; Marcus Schweigert; Thomas Beinert; Bernd Flath; Orhan Sezer; Kurt Possinger
Journal:  Invest New Drugs       Date:  2005-03       Impact factor: 3.850

10.  Gemcitabine combined with oxaliplatin in pretreated patients with malignant pleural mesothelioma: an observational study.

Authors:  Athanasios Xanthopoulos; Torsten T Bauer; Torsten G Blum; Jens Kollmeier; Nicolas Schönfeld; Monika Serke
Journal:  J Occup Med Toxicol       Date:  2008-12-18       Impact factor: 2.646
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.